Moli Huang Selected Research

carrimycin

1/2022

Isovalerylspiramycin I suppresses non-small cell lung carcinoma growth through ROS-mediated inhibition of PI3K/AKT signaling pathway.

Join CureHunter, for free Research Interface BASIC access!

Take advantage of free CureHunter research engine access to explore the best drug and treatment options for any disease. Find out why thousands of doctors, pharma researchers and patient activists around the world use CureHunter every day.

Realize the full power of the drug-disease research graph!

Moli Huang Research Topics

Disease

9	Neoplasms (Cancer) 01/2022 - 09/2006
2	Ewing Sarcoma (Sarcoma, Ewing) 11/2020 - 01/2019
2	Multiple Myeloma 01/2018 - 06/2015
2	Hepatocellular Carcinoma (Hepatoma) 11/2013 - 01/2011
1	Metaplasia 01/2022
1	Squamous Cell Carcinoma of Head and Neck 01/2022
1	Adenocarcinoma of Lung 01/2022
1	Lung Neoplasms (Lung Cancer) 10/2020
1	Adenocarcinoma 01/2020
1	Carcinogenesis 09/2006

Drug/Important Bio-Agent (IBA)

2	EWS-FLI fusion proteinIBA 11/2020 - 01/2019
2	Transcription Factors (Transcription Factor)IBA 11/2020 - 01/2020
2	Long Noncoding RNAIBA 06/2015 - 11/2013
1	carrimycinIBA 01/2022
1	Anti-Bacterial Agents (Antibiotics)IBA 01/2022
1	CalciumIBA 01/2022
1	Immune Checkpoint InhibitorsIBA 01/2022
1	MacrolidesIBA 01/2022
1	Mitogen-Activated Protein Kinase Kinases (MEKs)IBA 10/2020
1	Insulin-Like PeptidesIBA 10/2020
1	Insulin (Novolin)FDA Link 10/2020
1	ChromatinIBA 01/2020
1	DNA (Deoxyribonucleic Acid)IBA 01/2020
1	Leukemia Inhibitory FactorIBA 01/2020
1	Oncogene Proteins (Oncogene Protein)IBA 01/2019
1	OTX015IBA 01/2018
1	Cyclin-Dependent Kinase Inhibitor p57IBA 11/2013
1	MicroRNAs (MicroRNA)IBA 01/2011
1	beta CateninIBA 09/2006

Therapy/Procedure

1	Immunotherapy 10/2020